Metabolic‐associated fatty liver disease in relation to site‐specific and multiple‐site subclinical atherosclerosis
Liver International · 2023-08 · 43 (8) · 1691-1698
DOI: 10.1111/liv.15591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 20.06.2023. Verfasst von Xinyu Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Atherosclerosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Fundamental Research Funds for the Central Universities, Peking University Start-up Grant, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Background & Aims Non‐alcoholic fatty liver disease (NAFLD) and the newly proposed metabolic‐associated fatty liver disease (MAFLD) were each associated with subclinical atherosclerosis. However, there is limited evidence on risk of atherosclerosis in individuals who meet the criteria for one but not the other. We aimed to investigate the associations of MAFLD or NAFLD status with site‐specific and multiple‐site atherosclerosis.
Methods
This is a prospective cohort study involving 4524 adults within the MJ health check‐up cohort. Logistic regression model was used to estimate odds ratios (ORs) and confidence intervals (CIs) for subclinical atherosclerosis (elevated carotid intima‐media thickness [CIMT], carotid plaque [CP], coronary artery calcification [CAC] and retinal atherosclerosis [RA]) associated with MAFLD or NAFLD status, MAFLD subtypes and fibrosis status.
Results
MAFLD was associated with higher risks of elevated CIMT, CP, CAC and RA (OR: 1.41 [95% CI 1.18–1.68], 1.23 [1.02–1.48], 1.60 [1.24–2.08], and 1.79 [1.28–2.52], respectively), whereas NAFLD per se did not increase risk of atherosclerosis except for elevated CIMT. Individuals who met both definitions or the definition for MAFLD but not NAFLD had higher risk of subclinical atherosclerosis. Among MAFLD subtypes, MAFLD with diabetes had the highest risk of subclinical atherosclerosis, but the associations did not differ by fibrosis status. Stronger positive associations were observed of MAFLD with multiple‐site than single‐site atherosclerosis.
Conclusions
In Chinese adults, MAFLD was associated with subclinical atherosclerosis, with stronger associations for multiple‐site atherosclerosis. More attention should be paid to MAFLD with diabetes, and MAFLD might be a better predictor for atherosclerotic disease than NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China.
- Meinian Institute of Health, Beijing, China.
- Peking University Health Science Center, Meinian Public Health Institute, Beijing, China.
- Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China.
- Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, China.
- MJ Health Care Group, Shanghai, China.
ORCID-Profile: Xinyu Wang, Sailimai Man, Yuanjie Pang
Förderung
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities, Peking University Start-up Grant
- Ministry of Science and Technology of the People's Republic of China
- Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, X., Zhang, R., Man, S., Lv, J., Yu, C., Yin, J., Wang, X., Deng, Y., Wang, B., Li, L., & Pang, Y. (2023). Metabolic‐associated fatty liver disease in relation to site‐specific and multiple‐site subclinical atherosclerosis. Liver International, 43(8), 1691-1698. https://doi.org/10.1111/liv.15591
Vancouver
Wang X, Zhang R, Man S, Lv J, Yu C, Yin J, et al. Metabolic‐associated fatty liver disease in relation to site‐specific and multiple‐site subclinical atherosclerosis. Liver International. 2023;43(8):1691-1698. doi:10.1111/liv.15591
BibTeX
@article{Wang2023,
author = {Wang, Xinyu and Zhang, Ruosu and Man, Sailimai and Lv, Jun and Yu, Canqing and Yin, Jianchun and Wang, Xiaona and Deng, Yuhan and Wang, Bo and Li, Liming and Pang, Yuanjie},
title = {Metabolic‐associated fatty liver disease in relation to site‐specific and multiple‐site subclinical atherosclerosis},
journal = {Liver International},
year = {2023},
volume = {43},
number = {8},
pages = {1691--1698},
doi = {10.1111/liv.15591}
}
EUVIMED